Chiasma Secures $11 Million
Chiasma Inc., a biotech company focused on enhanced oral delivery of proteins and small molecules, has raised $11 million in Series B recap funding ($9m called so far). Return backers include ARCH Venture Partners, MPM Capital, 7 Health Ventures, Ofer Hi-Tech and F2-ventures. The company had previously raised over $55 million, including a $44 million Series C round.
13 January 2009•4 mins read
